Psyence Group Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Psyence Group CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jody Aufrichtig	Co-Founder & Executive Chairman	3.8yrs	CA$150.00k	1.49% CA$ 41.6k
Alan Friedman	Independent Director	3.7yrs	Veri yok	1.93% CA$ 54.0k
Warwick Corden-Lloyd	Director	less than a year	CA$150.00k	0.37% CA$ 10.5k
AC Braddock	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PSYG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Psyence Group Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Psyence Group Inc., Annual General Meeting, Dec 16, 2024

Psyence Group Inc., Annual General Meeting, Jun 07, 2024

Psyence Group Inc. Announces Resignation of Marvin Singer as Board Member

Less than half of directors are independent

Psyence Group Inc. Appoints Christopher Bull to Board of Directors

Psyence Group Inc. Appoints AC Braddock to Scientific Advisory Board

Recent updates

Psyence Group Inc., Annual General Meeting, Dec 16, 2024

New major risk - Negative shareholders equity

Psyence Group Inc., Annual General Meeting, Jun 07, 2024

An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).

New major risk - Financial position

Psyence Group Inc. Announces Resignation of Marvin Singer as Board Member

New major risk - Negative shareholders equity

Psyence Group Inc. announced that it has received CAD 0.162697 million in funding

Less than half of directors are independent

New major risk - Market cap size

New major risk - Financial position

Psyence Group Inc. Appoints Christopher Bull to Board of Directors

Psyence Group Inc. Appoints AC Braddock to Scientific Advisory Board

Psyence Group Inc., Annual General Meeting, Mar 09, 2023

Psyence Group Inc. Announces Resignation of Gavin Basserabie from Board

Less than half of directors are independent

Psyence Group Inc. announced that it expects to receive CAD 1.22 million in funding

Psyence Group Inc. Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency

Less than half of directors are independent

Psyence Group Inc. Taps Another Pharma Exec to Drive Its Clinical Program

Less than half of directors are independent

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

Psyence Group Inc. announced that it expects to receive CAD 2 million in funding

Director has left the company

Psyence Group Announces Partnership with Base Pair Health

Psyence Group Inc. Announces Board Changes

Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at its Commercially Licensed Facility

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş